- Home
- MFH vs CDNA Comparison
MFH vs CDNA Comparison
Compare MFH & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- CDNA
- Stock Information
- Founded
- MFH 2011
- CDNA 1998
- Country
- MFH United States
- CDNA United States
- Employees
- MFH N/A
- CDNA N/A
- Industry
- MFH Finance: Consumer Services
- CDNA Medical Specialities
- Sector
- MFH Finance
- CDNA Health Care
- Exchange
- MFH Nasdaq
- CDNA Nasdaq
- Market Cap
- MFH 822.0M
- CDNA 712.2M
- IPO Year
- MFH N/A
- CDNA 2014
- Fundamental
- Price
- MFH $12.42
- CDNA $14.96
- Analyst Decision
- MFH
- CDNA Buy
- Analyst Count
- MFH 0
- CDNA 7
- Target Price
- MFH N/A
- CDNA $26.00
- AVG Volume (30 Days)
- MFH 311.3K
- CDNA 1.2M
- Earning Date
- MFH 12-04-2025
- CDNA 11-04-2025
- Dividend Yield
- MFH N/A
- CDNA N/A
- EPS Growth
- MFH N/A
- CDNA N/A
- EPS
- MFH N/A
- CDNA 1.22
- Revenue
- MFH $960,967.00
- CDNA $357,998,000.00
- Revenue This Year
- MFH N/A
- CDNA $12.73
- Revenue Next Year
- MFH N/A
- CDNA $11.90
- P/E Ratio
- MFH N/A
- CDNA $12.12
- Revenue Growth
- MFH 65.39
- CDNA 14.46
- 52 Week Low
- MFH $1.20
- CDNA $10.96
- 52 Week High
- MFH $36.77
- CDNA $26.37
- Technical
- Relative Strength Index (RSI)
- MFH 47.80
- CDNA 50.95
- Support Level
- MFH $8.41
- CDNA $14.27
- Resistance Level
- MFH $11.98
- CDNA $16.60
- Average True Range (ATR)
- MFH 1.93
- CDNA 0.83
- MACD
- MFH -0.25
- CDNA 0.05
- Stochastic Oscillator
- MFH 70.86
- CDNA 33.85
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.